Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06382051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06382051 · ClinicalTrials.gov record · last posted 2026-08-21

Modifying PEST for Psoriatic Arthritis Screening

Study acronym: ScreenX
StatusRecruiting
PhaseNot applicable
Started2025-01-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.

Protocol amendment history 4 changes detected by DataLookout

2026-08-22
Primary completion pushed: 2026-08-28 → 2026-12-31
2026-07-17
Completion pushed: 2026-08-28 → 2026-12-31
2026-06-04
Trial sites expanded: 21 → 29 locations
2026-04-30
Trial sites expanded: 15 → 21 locations
Trial Details
NCT Number NCT06382051
Lead Sponsor Novartis Pharmaceuticals
Conditions Plaque Psoriasis, Psoriatic Arthritis
Enrollment 502 participants
Start Date 2025-01-23
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-21